KalVista Pharmaceuticals (KALV) Share-based Compensation (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Share-based Compensation of $5.4 million in Q3 2025, up 47.69% quarter-over-quarter from $3.6 million in Q2 2025, and up 76.94% year-over-year from $3.0 million in Q3 2024.
KalVista Pharmaceuticals' Share-based Compensation history runs 12 years deep, the most recent figure standing at $5.4 million for Q3 2025.
- In Q3 2025, Share-based Compensation rose 76.94% year-over-year to $5.4 million; the TTM figure through Jul 2025 stood at $15.1 million (up 34.97% YoY), while the FY2025 annual figure was $12.3 million, down 43.92% from the prior year.
- Share-based Compensation came in at $5.4 million for Q3 2025 at KalVista Pharmaceuticals, up from $3.6 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $5.4 million in Q3 2025 to a low of $1.2 million in Q1 2021.
- A 5-year average of $2.9 million and a median of $2.8 million in 2021 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation jumped 215.69% in 2021 and slipped 22.87% in 2022, its largest moves.
- KalVista Pharmaceuticals' Share-based Compensation stood at $2.9 million in 2021, then dropped by 12.38% to $2.5 million in 2022, then increased by 27.97% to $3.2 million in 2023, then slipped by 6.49% to $3.0 million in 2024, then soared by 79.36% to $5.4 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $5.4 million, $3.6 million, and $3.0 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 5.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 5.38 Mn |
| Jul 31, 2025 | 5.38 Mn |
| Apr 30, 2025 | 3.64 Mn |
| Apr 30, 2025 | 3.64 Mn |
| Oct 31, 2024 | 3.00 Mn |
| Oct 31, 2024 | 3.00 Mn |
| Jul 31, 2024 | 3.04 Mn |
| Jul 31, 2024 | 3.04 Mn |
| Apr 30, 2024 | 2.20 Mn |
| Apr 30, 2024 | 2.20 Mn |
| Jan 31, 2024 | 2.71 Mn |
| Jan 31, 2024 | 2.71 Mn |
| Oct 31, 2023 | 3.21 Mn |
| Oct 31, 2023 | 3.21 Mn |
| Jul 31, 2023 | 3.25 Mn |
| Jul 31, 2023 | 3.25 Mn |
| Apr 30, 2023 | 2.44 Mn |
| Apr 30, 2023 | 2.44 Mn |
| Jan 31, 2023 | 2.33 Mn |
| Jan 31, 2023 | 2.33 Mn |
| Oct 31, 2022 | 2.51 Mn |
| Oct 31, 2022 | 2.51 Mn |
| Jul 31, 2022 | 2.64 Mn |
| Jul 31, 2022 | 2.64 Mn |
| Apr 30, 2022 | 2.65 Mn |
| Apr 30, 2022 | 2.65 Mn |
| Jan 31, 2022 | 2.78 Mn |
| Jan 31, 2022 | 2.78 Mn |
| Oct 31, 2021 | 2.86 Mn |
| Oct 31, 2021 | 2.86 Mn |
| Jul 31, 2021 | 2.80 Mn |
| Jul 31, 2021 | 2.80 Mn |
| Apr 30, 2021 | 3.44 Mn |
| Apr 30, 2021 | 3.44 Mn |
| Jan 31, 2021 | 1.24 Mn |
| Jan 31, 2021 | 1.24 Mn |
| Oct 31, 2020 | 1.25 Mn |
| Oct 31, 2020 | 1.25 Mn |
| Jul 31, 2020 | 1.19 Mn |
| Jul 31, 2020 | 1.19 Mn |
| Apr 30, 2020 | 1.09 Mn |
| Apr 30, 2020 | 1.09 Mn |
| Jan 31, 2020 | 1.12 Mn |
| Jan 31, 2020 | 1.12 Mn |
| Oct 31, 2019 | 1.16 Mn |
| Oct 31, 2019 | 1.16 Mn |
| Jul 31, 2019 | 1.07 Mn |
| Jul 31, 2019 | 1.07 Mn |
| Apr 30, 2019 | 846,000.00 |
| Apr 30, 2019 | 846,000.00 |
| Jan 31, 2019 | 797,000.00 |
| Jan 31, 2019 | 797,000.00 |
| Oct 31, 2018 | 976,000.00 |
| Oct 31, 2018 | 976,000.00 |
| Jul 31, 2018 | 347,000.00 |
| Jul 31, 2018 | 347,000.00 |
| Apr 30, 2018 | 281,000.00 |
| Apr 30, 2018 | 281,000.00 |
| Jan 31, 2018 | 285,000.00 |
| Jan 31, 2018 | 285,000.00 |
| Oct 31, 2017 | 273,000.00 |
| Oct 31, 2017 | 273,000.00 |
| Jul 31, 2017 | 221,000.00 |
| Jul 31, 2017 | 221,000.00 |
| Apr 30, 2017 | 166,000.00 |
| Apr 30, 2017 | 166,000.00 |
| Jan 31, 2017 | 161,000.00 |
| Jan 31, 2017 | 161,000.00 |
| Oct 31, 2016 | 63,000.00 |
| Oct 31, 2016 | 63,000.00 |
| Jul 31, 2016 | 4,000.00 |
| Jul 31, 2016 | 4,000.00 |
| Mar 31, 2016 | 368,000.00 |
| Mar 31, 2016 | 368,000.00 |
| Dec 31, 2015 | 341,000.00 |
| Dec 31, 2015 | 341,000.00 |
| Sep 30, 2015 | 289,000.00 |
| Sep 30, 2015 | 289,000.00 |
| Jun 30, 2015 | 37,000.00 |
| Jun 30, 2015 | 37,000.00 |
| Mar 31, 2015 | 118,000.00 |
| Mar 31, 2015 | 118,000.00 |
| Sep 30, 2014 | 100,000.00 |
| Sep 30, 2014 | 100,000.00 |
| Jun 30, 2014 | 50,000.00 |
| Jun 30, 2014 | 50,000.00 |
| Mar 31, 2014 | 59,000.00 |
| Mar 31, 2014 | 59,000.00 |